New cancer drugs much more effective against endometrial tumors when estrogen is low
Studies on endometrial cancer cell lines have shown that PARP inhibition induces cell death when the tumor-suppressor gene PTEN is missing — a defect found in about 80 percent of human endometrial cancers.
However, the UCLA researchers wanted to test the inhibitors in a laboratory model with a tumor microenvironment that closely resembled human endometrial cancer to see if this therapy would be effective, said senior study author Dr. Sanaz Memarzadeh, an assistant professor of obstetrics and gynecology and director of the G.O. Discovery Lab at UCLA.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
